The aim of this systematic review was to assess AKI (acute kidney injury) in adult patients, treated with vancomycin (V) + piperacillin/tazobactam (PT) compared to V monotherapy. Studies were found in Pubmed, Web of Science and Scopus databases. Articles not in English, pediatric studies and case reports were excluded. A study is eligible for inclusion if the adjusted Odds ratio (aOR) for AKI in V + PT compared to V monotherapy groups, could be extracted or determined from available data. Six retrospective cohort studies were eligible for inclusion criteria and so they were included in the analysis. All studies separately showed a significant higher risk of developing AKI (OR > 1, p < 0.05) in V + PT group compared to V monotherapy group. Considering the methodological difference of included studies, a random effect model was preferred. The model showed a pooled significant higher risk of developing AKI [OR 2.77 (95% CI 1.94, 3.96), p < 0.0001] in V + PT group compared to V group. Association of V and PT appears to be associated with a greater risk of AKI compared to V in monotherapy. These results may serve as the impetus for further evaluation into true mechanisms behind this additive nephrotoxic effect and its potential implications on mortality.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Magill SS, Edwards JR, Beldavs ZG et al (2011) Emerging infections program healthcare- associated infections and antimicrobial use prevalence survey team. 2014. prevalence of antimicrobial use in US acute care hospitals. JAMA 312:1438–1446
Gin A, Dilay L, Karlowsky JA et al (2007) Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 5(3):365–383
Meaney CJ, Hynicka LM, Tsoukleris MG (2014) Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34:653–661
Gomes DM, Smotherman C, Birch A et al (2014) Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or cefepime. Pharmacotherapy 34:662–669
Ephraim RKD, Darkwah KO, et al (2016) Assessment of the RIFLE criteria for the diagnosis of acute kidney injury; a retrospective study in South-Western Ghana. BMC Nephrol. 17(1):99.
Wells GA, Shea B, O’Connell D, et al. (2011) The Newcastle–Ottawa Scale (nos) for assessing the quality of nonrandomized studies in meta-analysis. Accessed 25 November 2012.
Kim T, Kandiah S, Patel M et al (2015) Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes 17(8):579
Rutter WC, Cox JN, Martin CA, Erratum for Rutter et al. (2017) Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime. Antimicrob Agents Chemother 61(4)
Anderson CW, Cazares KS, Lustik MB, et al (2017) Vancomycin vs. vancomycin/piperacillin–tazobactam-associated acute kidney injury in non-critically ill patients at a tertiary care military treatment facility. Mil Med 182(9):e1773–e1778.
Balcı C, Uzun Ö, Arıcı M et al (2018) Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents 52(2):180–184
Carreno J, Smiraglia T, Hunter C et al (2018) Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. Int J Antimicrob Agents 52(5):643–650
Eberle H, Rogers M, Lee M et al (2018) A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam. Infect Dis Clin Pract 26(1):23–26
Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111
Hammond DA, Smith MN et al (2017) Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 64:5
Elyasi S, Khalili H, Dashti-Khavidaki S, et al (2012). Vancomycin- induced nephrotoxicity: mechanism, incidence, risk factors, and special populations. A literature review. Eur J Clin Pharmacol 68:1243–1255.
Navalkele B, Pogue JM, Karino S, et al (2016). Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin/tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis.
Hammond DA, Smith MN, Li C, et al (2017). Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 64(5):666–674.
Ragab AR, AL Mazroua MK, Al Harony MK (2013) Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children. Infect Dis Ther 2:37–46
Conflict of interest
The authors declare that they have no conflict of interest.
Statements of human and animal rights
This article does not contain any study with human and animals by any of the authors.
For this type of study, formal consent is not required.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ciarambino, T., Giannico, O.V., Campanile, A. et al. Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review. Intern Emerg Med (2020). https://doi.org/10.1007/s11739-020-02287-2
- Acute kidney injury
- Adult patients